Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases

Time: 9:30 am
day: Conf Day 2

Details:

  • Understanding the mechanism of action and preclinical data for the therapeutic candidate
  • Highlighting key formulation and delivery considerations to be on-target and measuring off-target effects
  • Identifying the next steps for the therapeutic candidate

Speakers: